cefazolin: A New Hope for Methicillin-Susceptible Staph Infections?
As an expert in infectious diseases, I was intrigued to read about the recent findings on cefazolin's effectiveness in treating methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia. The study, published in the New England Journal of Medicine, suggests that cefazolin may be a superior treatment option for this common and often deadly infection.
What makes this particularly fascinating is the long-standing preference for antistaphylococcal penicillins over cefazolin. Clinicians have traditionally opted for cloxacillin and flucloxacillin due to habit, guidelines, and a theoretical concern about the cefazolin inoculum effect (CIE). The CIE relates to findings from the laboratory, where some MSSA strains produce a beta-lactamase that breaks down cefazolin. Additionally, case reports had suggested that cefazolin treatment may fail when infections are caused by bacteria that can cause CIE.
However, the SNAP trial, an international open-label platform trial, found that cefazolin met noninferiority for 90-day mortality (15% vs 17%) against the antistaphylococcal penicillins. Patients assigned to cefazolin also had a lower incidence of acute kidney injury within 14 days versus those taking the antistaphylococcal penicillins (13.9% vs 19.6%).
In my opinion, these results should allay theoretical concerns about the cefazolin inoculum effect (CIE) when considering this first-generation cephalosporin in MSSA bacteremia. The SNAP study shows that cefazolin's effectiveness was not hindered by CIE, and it may even be more effective than antistaphylococcal penicillins.
One thing that immediately stands out is the potential impact of these findings on clinical practice. If cefazolin is indeed a superior treatment option, it could change the way clinicians approach MSSA bacteremia. Personally, I think it's time to re-evaluate our guidelines and consider cefazolin as the preferred antibiotic for this infection.
However, it's important to note that the study has limitations, including its open-label design and the limited control over clinician decisions after patients were randomized to treatment. Practice variability across sites could have introduced heterogeneity in results.
A detail that I find especially interesting is the potential role of adjunctive clindamycin in the treatment of MSSA bacteremia. The SNAP trial also included an arm comparing adjunctive clindamycin in MRSA, MSSA, or PSSA. While the results of this arm are not yet available, it's possible that clindamycin could enhance the effectiveness of cefazolin or other antibiotics.
In conclusion, the SNAP trial suggests that cefazolin may be a more effective treatment option for MSSA bacteremia than previously thought. While further research is needed to confirm these findings and address the study's limitations, it's clear that cefazolin has the potential to change the way we treat this common and often deadly infection.
From my perspective, the bottom line for clinicians treating MSSA bacteremia is clear: cefazolin should be the preferred antibiotic. In my practice, the only time I am using antistaphylococcal penicillins is where there has been a relapse of invasive MSSA following an appropriate treatment course with cefazolin.
